ProPhase Labs, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $1.49 per share as of 2017-12-31, per its 10-K/A filed 2018-08-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2018-08-20
- 2017-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $1.49; Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed $1.37.
- 2016-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $1.37.
- 2015-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $1.37.
- 2014-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $1.37.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2017-12-31 | $1.49 10-K/A · filed 2018-08-20 | $1.37 10-K · filed 2018-03-28 |
| 2016-12-31 | $1.37 10-K · filed 2017-02-24 | |
| 2015-12-31 | $1.37 10-K · filed 2016-03-29 | |
| 2014-12-31 | $1.37 10-K · filed 2015-03-27 | |
| 2013-12-31 | $1.93 10-K · filed 2014-03-27 | |
| 2012-12-31 | $2.56 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |